Miconazole — Discount Pricing

Other medications in Dermatology

• Mometasone Furoate Cream
• Mupirocin
• Mupirocin Ointment
• Nystatin Topical
• Permethrin
• Pimecrolimus
• Podophyllotoxin
• Ruxolitinib Cream

About Miconazole

Miconazole is a trusted antifungal medication used to treat a variety of fungal infections affecting the skin, nails, and other areas. Whether you're dealing with athlete's foot, jock itch, or candida, miconazole can provide effective relief. TheDrugClub members enjoy significant savings on this medication, including $0 co-pays and convenient free home delivery.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Miconazole is approved for (FDA label)

ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults. ORAVIG is an azole antifungal indicated for the local treatment of oropharyngeal candidiasis in adults.

Source: Read the full FDA label on DailyMed. Label effective date: January 8, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Miconazole (FDA label)

ORAVIG is a buccal tablet containing 50 mg of miconazole. ORAVIG tablets are round, off-white tablets, with a rounded side and a flat side. The tablets are marked with an “L” on the flat side. 50 mg buccal tablets

Source: FDA prescribing information (DailyMed). Set ID: dc2427ff-e566-4b48-b289-9e51c011250a. SPL document ID: 47da8a7f-0d47-f1cd-e063-6394a90a84ad. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Miconazole (FDA label)

The following serious adverse drug reactions are discussed in detail in other sections of labeling: Hypersensitivity reactions [see Warnings and Precautions (5.1)] Most common adverse reactions (≥2%) are: diarrhea, headache, nausea, dysgeusia, upper abdominal pain, and vomiting (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Galt Pharmaceuticals, LLC Marietta, GA 30067 at 1-833-757-0904 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: dc2427ff-e566-4b48-b289-9e51c011250a. SPL document ID: 47da8a7f-0d47-f1cd-e063-6394a90a84ad. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Miconazole (FDA label)

ORAVIG is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to miconazole, milk protein concentrate, or any other component of the product. Known hypersensitivity to miconazole, milk protein concentrate, or any other component of the product.

Source: FDA prescribing information (DailyMed). Set ID: dc2427ff-e566-4b48-b289-9e51c011250a. SPL document ID: 47da8a7f-0d47-f1cd-e063-6394a90a84ad. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Miconazole (FDA label)

Hypersensitivity reactions: Anaphylactic reactions have been reported in patients receiving miconazole. Discontinue ORAVIG immediately at the first sign of hypersensitivity (5.1). 5.1 Hypersensitivity Allergic reactions, including anaphylactic reactions and hypersensitivity, have been reported with the administration of miconazole products, including ORAVIG. Discontinue ORAVIG immediately at the first sign of hypersensitivity. There is no information regarding cross-hypersensitivity between miconazole and other azole antifungal agents. Monitor patients with a history of hypersensitivity to azoles.

Source: FDA prescribing information (DailyMed). Set ID: dc2427ff-e566-4b48-b289-9e51c011250a. SPL document ID: 47da8a7f-0d47-f1cd-e063-6394a90a84ad. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Miconazole (FDA label)

Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out.

Source: FDA prescribing information (DailyMed). Set ID: dc2427ff-e566-4b48-b289-9e51c011250a. SPL document ID: 47da8a7f-0d47-f1cd-e063-6394a90a84ad. Label effective date: January 8, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.